PET Imaging Evaluation of [11C]SY08
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age50-80
SponsorMassachusetts General Hospital
About this trial
The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls.
The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are:
1. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in healthy individuals. 2. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in patients with alpha synuclein aggregates in the brain, including PD, DLB and MSA. 3. To determine human dosimetry of \[11C\]SY08 in healthy individuals
An intravenous bolus injection of \[11C\]SY08 will be administered per subject for brain PET imaging.
Eligibility criteria
Qualifiers
Age 50-80
Be able to provide written informed consent or assent
Be able to read, speak and understand English (The investigators do not have the resources necessary to properly study non-English speaking patients in this study, given that translation and validation of the assessment tools would be necessary)
Be willing and able to participate in one PET/MRI scanning session
Disqualifiers
General Exclusion Criteria (All Subjects)
History of vascular risk factors (e.g. hypertension, hyperlipidemia), if not well-controlled
Major psychiatric disease (e.g.schizophrenia)
History of stroke
Trial design
Treatments tested in this trial
- C11-SY08
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov